1. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
- Author
-
Tang Y, Zhang DY, and Wu XM
- Subjects
- Antimycin A chemistry, Antimycin A pharmacology, Benzopyrans chemistry, Benzopyrans pharmacology, Biphenyl Compounds chemistry, Biphenyl Compounds pharmacology, Cell Line, Tumor, Drug Design, Drugs, Chinese Herbal chemistry, Drugs, Chinese Herbal pharmacology, Gossypol chemistry, Gossypol pharmacology, Humans, Nitriles chemistry, Nitriles pharmacology, Nitrophenols chemistry, Nitrophenols pharmacology, Piperazines chemistry, Piperazines pharmacology, Proto-Oncogene Proteins c-bcl-2 pharmacology, Structure-Activity Relationship, Sulfonamides chemistry, Sulfonamides pharmacology, Thiazoles chemistry, Thiazoles pharmacology, Thiazolidinediones, bcl-X Protein pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Apoptosis drug effects, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors, bcl-X Protein antagonists & inhibitors
- Abstract
Apoptosis is an essential factor in keeping homeostasis of the organism. Apoptosis is regulated by a series of cytokines. Bcl-2 family proteins are key regulators of apoptosis. The Bcl-2 family includes both anti- and pro-apoptotic proteins with opposing biological functions. Their interaction regulates the transmission of the apoptosis signal. High expression of anti-apoptotic members such as Bcl-2 and Bcl-xL are commonly found in human cancers. In recent years, following the disclosing of the crystal structures of Bcl-2 family proteins, researchers have paid attention to the development of the small molecule inhibitors of Bcl-2 family proteins. This article reviews the progress in this field from the view of drug design.
- Published
- 2008